Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)


ForecastChart

Previous Close

$427.05

52W Range

$200.63 - $457.16

50D Avg

$366.62

200D Avg

$326.11

Market Cap

$9.37B

Avg Vol (3M)

$379.68K

Beta

-1.02

Div Yield

-

MDGL Company Profile


Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

528

IPO Date

Feb 06, 2007

Website

MDGL Performance


Latest Earnings Call Transcripts


Q1 22May 09, 22 | 12:56 PM
Q2 15Aug 06, 15 | 5:00 PM
Q1 15May 07, 15 | 5:00 PM

Peer Comparison


TickerCompany
VKTXViking Therapeutics, Inc.
APLSApellis Pharmaceuticals, Inc.
AKROAkero Therapeutics, Inc.
TickerGate Footer Logo

Tickergate is an advanced stock research & comparison platform for informed data-driven investment decisions. 100% customizable, institutional-grade data, easy to use.

Company

AboutContact

Connect

LinkedIn

©2025 Tickergate

Tickergate does not provide financial advices and does not issue recommendations or offers to buy stocks of sell any securities. Information is provided 'as-is' and solely for informational purposes as an advice. Tickergate does not bear any responsibility or any losses or damages that may occur as a result of reliance on this data.
Start a conversation

Ask me anything about stocks, markets, or financial data.

Market Trends
Compare Stocks